A
Angela Macleod
Publications - 3
Citations - 2885
Angela Macleod is an academic researcher. The author has contributed to research in topics: Gefitinib & Lung cancer. The author has an hindex of 1, co-authored 2 publications receiving 2837 citations.
Papers
More filters
Journal ArticleDOI
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
Masahiro Fukuoka,Seiji Yano,Giuseppe Giaccone,Tomohide Tamura,Kazuhiko Nakagawa,Jean-Yves Douillard,Yutaka Nishiwaki,Johan Vansteenkiste,Shinzoh Kudoh,Danny Rischin,Richard Eek,Takeshi Horai,Kazumasa Noda,Ichiro Takata,Egbert F. Smit,Steven D. Averbuch,Angela Macleod,A. Feyereislova,Rui Ping Dong,José Baselga +19 more
TL;DR: Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in patients with pretreated advanced non-small-cell lung cancer.
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
Masahiro Fukuoka,Seiji Yano,Giuseppe Giaccone,Tomohide Tamura,Kazuhiko Nakagawa,Jean-Yves Douillard,Yutaka Nishiwaki,Johan Vansteenkiste,Shinzoh Kudoh,Danny Rischin,Richard Eek,Takeshi Horai,Kazumasa Noda,Ichiro Takata,Egbert F. Smit,Steven D. Averbuch,Angela Macleod,A. Feyereislova,Ruiping Dong,José Baselga +19 more
TL;DR: In this paper , the authors evaluated the efficacy and tolerability of two doses of gefitinib (Iressa [ZD1839]), a novel epidermal growth factor receptor tyrosine kinase inhibitor, in patients with pretreated advanced non-small-cell lung cancer (NSCLC).
Multi-Institutio nal R andomized P hase I I T rial o f G efitinib f or Previously T reated P atients W ith A dvanced N on-Small-Cell Lung C ancer
Masahiro Fukuoka,Seiji Yano,Giuseppe Giaccone,Tomohide Tamura,Kazuhiko Nakagawa,Jean-Yves Douillard,Yutaka Nishiwaki,Johan Vansteenkiste,Shinzoh Kudoh,Danny Rischin,Richard Eek,Takeshi Horai,Kazumasa Noda,Ichiro Takata,Egbert F. Smit,Steven D. Averbuch,Angela Macleod,Andrea Feyereislova,Rui-Ping Dong +18 more
TL;DR: Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC and showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.